Broadly neutralizing monoclonal antibodies may hold the key to developing an effective vaccine against hepatitis C, suggests a recent review.
- While vaccines have been successfully developed to combat numerous viral infections, one has yet to be created against hepatitis C.
- The authors point out 2 reasons for the delay: The hepatitis C virus is genetically diverse, and the virus has the ability of evade the body’s immune system.
- Several broadly neutralizing human monoclonal antibodies (bNABs) are now available against the hepatitis C virus.
- These bNABs are capable of targeting conserved HCV epitopes and have been proven effective in animal studies.
Kinchen VJ, Cox AL, Bailey JR. Can broadly neutralizing monoclonal antibodies lead to a hepatitis C virus vaccine? [Published online ahead of print April 24, 2018]. Trends Microbiol. doi:10.1016/j.tim.2018.04.002.
This Week's Must Reads
Must Reads in Vaccines
Vaccination for Prevention of Herpes Zoster, Ann Intern Med; ePub 2019 Feb 19; Prosser, et al